Virology Resource Core

病毒学资源核心

• 批准号: 10688358
• 负责人: Andrew S. Pekosz
• 金额: $ 21.11万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10688358
• 关键词: 2019-nCoV; Amino Acids; Antibody Response; Biological Assay; COVID-19; COVID-19 surveillance; Carbohydrates; Cell Culture Techniques; Cell Line; Cells; Clinical; Complex; Containment; Data; Doctor of Philosophy; Ensure; Generations; Immunity; Influenza; International; Laboratories; Lead; Mammalian Cell; Measures; Methods; Pathogenesis; Pathology; Peptides; Plaque Assay; Post-Translational Protein Processing; Production; Protein Binding Domain; Proteins; Protocols documentation; Public Health; Reagent; Recombinant Proteins; Reproducibility; Research Personnel; Research Project Grants; Resources; SARS coronavirus; SARS-CoV-2 infection; Serology; Source; Standardization; T-Lymphocyte; Testing; Time; Universities; Viral Antigens; Virion; Virus; Virus Diseases; Work; biosafety level 3 facility; experience; experimental study; improved; laboratory experience; laboratory facility; milligram; particle; protein function; reagent standardization; receptor binding; repository; respiratory virus; response; viral RNA; virology

JH-EPICS Virology Resource Core (VRC) Summary The Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2 (JH-EPICS) aims to systematically analyze the innate, T cell, and antibody responses that either protect or cause pathology during SARS-CoV-2 infection. In order to accurately accomplish the Specific Aims within the three JH-EPICS Research Projects, a consistent and reliable source of virus-specific reagents and methods is required. The Virology Resource Core (VRC) is tasked with providing SARS-CoV-2-specific reagents and access to BSL3 facilities to perform experiments with virus infected cells for the three JH-EPICS Research Projects. The VRC draws on the expertise of Andrew Pekosz, PhD (Lead) and Michael Betenbaugh, PhD (Co-Lead) to generate these reagents. The VRC will produce recombinant proteins and, in particular, proteins with complex carbohydrate moieties. The VRC has the ability to use mammalian cells to express small or large quantities of purified proteins that will be used by all the JH-EPICS Research Projects to measure viral antigen specific responses. The Lead of the VRC has experience with respiratory viruses, such as influenza, SARS-CoV, and SARS-CoV-2, which will enable the VRC to rigorously and accurately grow and provide the JH-EPICS Research Projects with a consistent source of virus particles or infected cell lysates that have been inactivated and can be used in laboratories outside of BSL3-containment. The VRC will provide the expertise and access to facilities necessary to perform experiments on virus-infected cells, which will allow the JH-EPICS investigators to validate results with live virus. The centralized production of these reagents, the use of standardized protocols for virus infections, and consistent use across JH-EPICS Research Projects will improve the quality, rigor, and reproducibility of data to increase the public health significance of the JH-EPICS studies.

JH-EPICS病毒学资源核心（VRC）摘要 约翰·霍普金斯（Johns Hopkins 系统地分析了保护或在 SARS-COV-2感染。为了准确实现三个JH epics中的特定目标 需要研究项目，是一种一致且可靠的病毒特异性试剂和方法来源。这 病毒学资源核心（VRC）的任务是提供SARS-COV-2特异性试剂并访问BSL3 为三个JH-EPICS研究项目进行病毒感染细胞进行实验的设施。 VRC 利用Andrew Pekosz博士（领导）和Michael Betenbaugh博士（共同领导）的专业知识来产生 这些试剂。 VRC将产生重组蛋白，尤其是具有复杂的蛋白质 碳水化合物部分。 VRC具有使用哺乳动物细胞表达少量或大量的能力 所有JH-EPICS研究项目都将使用纯化的蛋白质来测量病毒抗原特异性 回答。 VRC的铅具有呼吸道病毒的经验，例如流感，SARS-COV和 SARS-COV-2，这将使VRC能够严格，准确地生长并提供JH-Epics 具有一致的病毒颗粒或感染细胞裂解物的一致来源的研究项目已被灭活 并且可以用于BSL3范围内的实验室。 VRC将提供专业知识和访问 为对感染病毒的细胞进行实验所需的设施，这将允许JH-Epics 研究人员通过实时病毒验证结果。这些试剂的集中生产，使用 病毒感染的标准化方案，以及JH-EPIC研究项目的一致使用 提高数据的质量，严格和可重复性，以提高JH-EPIC的公共健康意义 研究。